FDA
-
-
-
-
-
-
-
Flexion Therapeutics (FLXN) Announces Inclusion of ZILRETTA in AAOS Clinical Practice Guidelines for Management of Knee Osteoarthritis
-
-
-
-
-
-
-
Flexion Therapeutics Announces Appointment of William T. Andrews, M.D., F.A.C.P., as Chief Medical Officer
-
-
-
-
-
-
-
National Basketball Retired Players Association, Sheryl Swoopes and Flexion Therapeutics Announce Partnership to Raise Awareness of ZILRETTA®
-
-
-
-
-
-
-
Flexion Therapeutics Reports Second-Quarter 2020 Financial Results and Recent Business Highlights
-
-
-
-
-
-
-
Flexion Therapeutics (FLXN) Announces ZILRETTA License Agreement, Provides Business Update Amid Coronavirus Pandemic
-
-
-
-
-
-
-
Flexion Therapeutics (FLXN) Announces Prelim. Q4 and FY Results and FY20 Guidance
-
-
-
-
-
-
-
Flexion Therapeutics (FLXN) Announces FDA Approval of sNDA to Revise ZILRETTA Product Label
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

